R & D

R & D

Pharmaceutical research and development updates

iNtRON Confirms Efficacy Of ‘Inhalation Anthrax’-fighting DrugiNtRON Confirms Efficacy Of ‘Inhalation Anthrax’-fighting Drug
iNtRON Confirms Efficacy Of ‘Inhalation Anthrax’-fighting Drug

iNtRON has announced the completion of an efficacy evaluation study of BAL200

Mar 6, 2023 R & D
SynaptixBio Secures FDA Rare Paediatric Disease Designation To Develop Treatments For LeukodystrophySynaptixBio Secures FDA Rare Paediatric Disease Designation To Develop Treatments For Leukodystrophy
SynaptixBio Secures FDA Rare Paediatric Disease Designation To Develop Treatments For Leukodystrophy

SynaptixBio has received FDA Rare Paediatric Disease designation to develop new treatments for rare disease TUBB4a leukodystropy

Mar 6, 2023 R & D
TheracosBio’s Oral Drug Approved By FDA For Adults With Type 2 DiabetesTheracosBio’s Oral Drug Approved By FDA For Adults With Type 2 Diabetes
TheracosBio’s Oral Drug Approved By FDA For Adults With Type 2 Diabetes

TheracosBio has announced that bexaglifozin has been approved by the FDA for the treatment of adult patients with type 2 diabetes, despite originally being indicated for cats with diabetes

Mar 6, 2023 R & D
Johnson & Johnson’s Ethicon Undertakes First Robot-assisted Kidney Stone RemovalJohnson & Johnson’s Ethicon Undertakes First Robot-assisted Kidney Stone Removal
Johnson & Johnson’s Ethicon Undertakes First Robot-assisted Kidney Stone Removal

J&J's Ethicon has announced that it has undertaken its first robot-assisted kidney stone removal using its Monarch Platform

Mar 6, 2023 R & D
New Study Shares Effectiveness Of Asthma Drug Compared To Standard Of CareNew Study Shares Effectiveness Of Asthma Drug Compared To Standard Of Care
New Study Shares Effectiveness Of Asthma Drug Compared To Standard Of Care

The University of Plymouth has co-authored a new study, published in The Lancet, which shows how an asthma drug, commercially known as Relvar Ellipta, was more effective than patients’ usual care at improving their asthma control.

Feb 1, 2023 R & D
New Blood Test Appears To Detect Hidden CancerNew Blood Test Appears To Detect Hidden Cancer
New Blood Test Appears To Detect Hidden Cancer

Biotech company Guardant Health has announced that its blood test-based cancer screening technique appears to be effective: the liquid biopsy detected cases of colorectal cancer in 83% of patients who had the disease. It also correctly detected people who did not have colorectal cancer 90% of the time. However, some investors are disappointed with the technology’s ability to detect precancerous tumours.

Feb 1, 2023 R & D
Belharra Therapeutics And Genentech Join Forces For Small Molecule Medicine DevelopmentBelharra Therapeutics And Genentech Join Forces For Small Molecule Medicine Development
Belharra Therapeutics And Genentech Join Forces For Small Molecule Medicine Development

US-based biotech companies Belharra Therapeutics and Genentech have announced a multi year partnership to lead the discovery and development of small molecule medicines in multiple therapeutic areas, including oncology, immune-oncology, autoimmune and neurodegenerative diseases.

Feb 1, 2023 R & D
New Insights Into HIV Vaccine Revealed By ResearchersNew Insights Into HIV Vaccine Revealed By Researchers
New Insights Into HIV Vaccine Revealed By Researchers

Promising results announced from human trial of new HIV vaccine

Dec 1, 2022 R & D
Amgen’s Obesity Drug Appears Promising With Few Side EffectsAmgen’s Obesity Drug Appears Promising With Few Side Effects
Amgen’s Obesity Drug Appears Promising With Few Side Effects

Amgen Inc’s new obesity drug has appeared promising in its small phase 1 trial, meaning it will be able to go ahead with a larger mid-stage trial in 2023. The trial demonstrated that patients were able to maintain their weight loss for 70 days following the highest dose of the drug, known as AMG133.

Dec 1, 2022 R & D
Collaboration Between Biontech & Ryvu To Develop & Commercialise Immuno-modulatory Small MoleculesCollaboration Between Biontech & Ryvu To Develop & Commercialise Immuno-modulatory Small Molecules
Collaboration Between Biontech & Ryvu To Develop & Commercialise Immuno-modulatory Small Molecules

Ryvu Therapeutics, a clinical-stage oncology therapeutics development company, has announced a collaboration with BioNTech, which will consist of two parts: multi-target research into several small molecule immunotherapy programmes and an exclusive licence agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.

Dec 1, 2022 R & D
Fda Grants Approval To Wise For Neuromonitoring Cortical StripFda Grants Approval To Wise For Neuromonitoring Cortical Strip
Fda Grants Approval To Wise For Neuromonitoring Cortical Strip

FDA approvals to WISE for neuromonitoring device

Dec 1, 2022 R & D
Pfizer Finds RSV Vaccine Is Effective In Older PatientsPfizer Finds RSV Vaccine Is Effective In Older Patients
Pfizer Finds RSV Vaccine Is Effective In Older Patients

Data from a Phase III clinical trial has shown that the Respiratory Syncytial Virus (RSV) vaccine is 85.7% effective when administered to patients 60 years and older, burgeoning hopes for a first bivalent RSV vaccine candidate.

Oct 27, 2022 R & D